

## **JAMES J. NAWARSKAS**

**Work Address:**

University of New Mexico  
College of Pharmacy  
1 University of New Mexico  
Albuquerque, NM 87131-0001  
voice: (505) 272-0584  
FAX: (505) 272-6749  
e-mail: JNawarskas@salud.unm.edu

**Home Address:**

805 Bosque Rd NE  
Albuquerque, NM 87113  
(505) 342-2252

**Date of Birth:**

July 15, 1970

**Place of Birth:**

Cleveland, Ohio

**Licensure:**

Pharmacist: Ohio 03-3-19995  
New Mexico RP-00006265

Pharmacist Clinician: New Mexico PC00000111

**Specialty Certification:**

Board Certified Pharmacotherapy Specialist

**EDUCATION:**

Aug. 1993-Sept. 1995

**Doctor of Pharmacy**  
State University of New York at Buffalo  
Buffalo, NY

Sept. 1988-June 1993

**Bachelor of Science in Pharmacy**  
University of Toledo  
Toledo, OH

**POST-GRADUATE TRAINING:**

Sept. 1995-Sept. 1997

**Fellowship in Cardiovascular Pharmacotherapy**  
Philadelphia College of Pharmacy and Science  
Philadelphia, PA  
Preceptor: Sarah A. Spinler, Pharm.D., FCCP

**OTHER TRAINING:**

Sept. 2014-June 2016	<b>Medical Education Scholar</b> School of Medicine University of New Mexico Albuquerque, NM
Aug. 1999-July 2001	<b>General Clinical Research Center Scholar</b> General Clinical Research Center University of New Mexico Health Sciences Center Albuquerque, NM Mentor: Mark Schuyler, M.D.

**FACULTY APPOINTMENTS:**

July 2003-present	<b>Associate Professor of Pharmacy (with tenure)</b> College of Pharmacy University of New Mexico Health Sciences Center Albuquerque, NM
Oct. 1997-June 2003	<b>Assistant Professor of Pharmacy</b> College of Pharmacy University of New Mexico Health Sciences Center Albuquerque, NM
Jan. 2000-June 2010	<b>Volunteer Graduate Faculty - Pharmacy Administration</b> College of Pharmacy University of New Mexico Health Sciences Center Albuquerque, NM
Sept. 1995-Sept. 1997	<b>Clinical Instructor in Pharmacy Practice</b> Philadelphia College of Pharmacy and Science Philadelphia, PA

**PROFESSIONAL PRACTICE EXPERIENCE:**

Oct. 1997-present

**Clinical Pharmacist**

Inpatient Cardiology Service (6-8 hours/week)

University of New Mexico Hospital

Role: Work directly with attending cardiologists, cardiology fellows, and medical housestaff to help optimize drug therapy for inpatients with cardiovascular disease

April 2002-May 2017

**Clinical Pharmacist**

Healthy Heart Clinic (4 hours/week)

University of New Mexico Hospital

Role: Work directly with patients and an attending physician and, through the use of patient history and physical assessment techniques, help optimize drug therapy for outpatients with cardiovascular disease

Feb. 1998-2011

**Clinical Pharmacist**

Heart Failure Clinic (4 hours/week)

University of New Mexico Hospital

Role: Work directly with patients and clinicians and, through the use of patient history and physical assessment techniques, help optimize drug therapy for outpatients with heart failure

July 1996-Sept. 1997

**Staff pharmacist**

Hospital of the University of Pennsylvania, Philadelphia, PA

June 1994-June 1995

**Staff pharmacist**

Veterans Affairs Medical Center, Buffalo, NY

## TEACHING EXPERIENCE:

### University of New Mexico Health Sciences Center

#### ***Course coordinator (Doctor of Pharmacy program)***

2018-present: Evidence-based Medicine (Pharmacy 832)  
2019-present: Integrated Pharmacotherapy II (Pharmacy 825)  
2016-2017: Pharmaceutical Care Laboratory II (Pharmacy 733L and Pharmacy 823)  
2009-2015: Advanced Cardiovascular Pharmacotherapy (Pharmacy 785)  
2008: Pharmacotherapeutics I (Pharmacy 739)  
2000-2003: Pharmacotherapeutics II (Pharmacy 752)

#### ***Clinical preceptor (Cardiology or Academia\*): Doctor of Pharmacy students***

2018-present: 10 Doctor of Pharmacy students per year  
(had 20 students in 2020 since I accepted students displaced from other rotation sites due to COVID restrictions)  
1998-2018: 8-16 Doctor of Pharmacy students per year

#### ***Clinical preceptor (Cardiology or Academia\*): Pharmacy Residents***

2018-present: 5-6 PGY1 residents/year; 1-2 PGY2 residents per year  
2017-2018: 2-3 PGY1 residents/year; 1-2 PGY2 residents per year  
2004-2016: 1-2 PGY1 residents per/year

Workload: 40 hours/week/learner; rotations are 4 weeks in duration

\* Academia rotation started in 2017; after that time, learner load is split between Cardiology and Academia.

#### ***Research preceptor: Pharmacy 748 and 758 (Research Project - Doctor of Pharmacy program)***

Class of 2002: 4 students  
Class of 2001: 7 students  
Class of 2000: 10 students


Mandated research discontinued in the curriculum starting with the Class of 2003

#### ***Clinical/Research Preceptor: Pharmacy 798 (Problems in Pharmacy - Doctor of Pharmacy program )***

Elective course for students interested in additional research and clinical experience

Caroline Small (Class of '14)  
Jason Koury (Class of '14)  
Lenka Hrebickova (Class of '04)  
David Wales (Class of '03)

*Course Instructor: Doctor of Pharmacy curriculum<sup>†\*</sup>*



□ Pharmacy 431, 432, 739, 751, 752, 788 (Pharmacotherapeutics)

■ Pharmacy 711, 712, 721, 722 (Problem-Based Learning)

■ Pharmacy 719 (Self-Care Therapeutics)

■ Pharmacy 733L (Pharmaceutical Care Lab)

■ Pharmacy 750, 789 (Physical Assessment & Clinical Skills)

■ Pharmacy 820, 835, 855 (Integrated Pharmacotherapy)

■ Pharmacy 832 (Evidence-Based Medicine)

■ Pharmacy 705, 715 (Pathophysiology)

■ Pharmacy 716 (Practical Patient Experience)

■ Pharmacy 728, 747 (Pharmacoepidemiology & Research Design)

■ Pharmacy 745 (Clinical Pharmacokinetics)

■ Pharmacy 785 (Advanced Cardiovascular Pharmacotherapy)

■ Pharmacy 823, 833 (Aspects of Patient Care)

■ Pharmacy 839 (Professional Development)

■ Pharmacy 850 (Clinical Capstone)

<sup>†</sup> Pharmacy 431 and 432 were part of the Bachelor of Science in Pharmacy curriculum

\* While course was active (i.e. some course offerings were discontinued during a given date range)

***Graduate Committee***

2018: Adam Henrie, MS  
2015: Mark Smith, PhD  
2014: Stan Snowden, MSCR

***ACPE-Accredited Continuing Education Courses***

2008-present: ACPE 104-999-07-064-L04-P  
Physical Assessment for the Pharmacist Clinician (30 CEU)  
16 contact hours

***Fellowship in Cardiovascular Pharmacotherapy***

2011-2016: Co-preceptor (with Joe Anderson).  
  
Fellows: Stan Snowden, Pharm.D. (2011-2014)  
Alex Sible, Pharm.D. (2015-2017)

***Residency in Cardiovascular Pharmacotherapy***

2003-2009: Co-preceptor (with Joe Anderson). Residents:  
  
Lauren Silus, Pharm.D. (2008-2009)  
Gretchen Ray, Pharm.D. (2007-2008)  
Jennifer Griego, Pharm.D. (2005-2006)  
Cara Leos, Pharm.D. (2004-2005)  
Briana Koertner, Pharm.D. (2003-2004)

***Philadelphia College of Pharmacy and Science***

Sept. 1995 - Sept. 1997:

***Clinical preceptor (cardiology):***

- 5 Doctor of Pharmacy students
- 2 Bachelor of Science in Pharmacy students

***Lecturer:***

- Clinical Pharmacokinetics (PP648; Doctor of Pharmacy students)
- Human Disorders and Pharmacotherapeutics (PP437; Doctor of Pharmacy and Bachelor of Science in Pharmacy students)

***Recitation instructor:***

- Introduction to Clinical Skills (Bachelor of Science in Pharmacy students)
- Human Disorders and Pharmacotherapeutics (Bachelor of Science in Pharmacy students)
- Doctor of Pharmacy Seminar

## RESEARCH EXPERIENCE, GRANTS, & CONTRACTS:

### Ongoing:

1. *The Impact of Online Interprofessional Education Experiences on Achievement of IPE Competencies in Pharmacy Students*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Morrison, AE, Hynson TW, McLaughlin SJ, Rogers, HH  
Amount funded: Unfunded  
Funding sources: Unfunded  
Percent effort: 10%  
Project period: 7/1/20 through 6/30/22  
Status: Project in progress

2. *Patient characteristics associated with eptifibatide use at a tertiary care academic medical center*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Godinez WR  
Co-Investigators: **Nawarskas JJ**, Sarangarm P, Kessler SG  
Amount funded: Unfunded  
Funding sources: Unfunded  
Percent effort: 5%  
Project period: 7/1/20 through 6/30/21  
Status: Project in progress

3. *Health Systems Data Management and Use of Team-Based Healthcare*

Research Affiliation: University of New Mexico Health Sciences Center and Lovelace Health System  
Principal Investigator: Anderson JR  
Co-Investigators: **Nawarskas JJ**  
Amount funded: \$52,269  
Funding sources: New Mexico Department of Health  
Percent effort: 5%  
Project period: 7/1/14 through 6/30/21  
Status: Project in progress; currently suspended due to COVID

### Completed:

1. *Standardized Patient Assessment of Communications in Pharmacy and Medical Students*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Fancovic E, Marshik P, Morrison A, Ortega A, Salazar K, Sible A, Takeda M, Vilay M  
Amount funded: \$3692  
Funding sources: American Association of Colleges of Pharmacy  
Percent effort: 10%  
Project period: 8/1/18 through 6/30/19  
Status: Manuscript in preparation

2. *The Impact of Formative Examinations on Information Retention in a Pharmacotherapy Course*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Smith GA, Newsome C  
Amount funded: Unfunded  
Funding sources: Unfunded  
Percent effort: 10%  
Project period: 1/1/16 through 6/30/18  
Status: Manuscript in preparation

3. *Effect of Environment on the Integrity of Sublingual Nitroglycerin Tablets*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Koury J, Felton LA  
Amount funded: Unfunded  
Funding sources: Unfunded  
Percent effort: 5%  
Project period: 7/1/13 through 6/30/16

4. *Development of Scholarship of Teaching and Learning Collaborative*

Research Affiliation: University of New Mexico College of Pharmacy  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Borrego ME, Godwin, DA, Hall PR, Hunter TS, Wittstrom KM, Thompson TA  
Amount funded: \$500  
Funding sources: University of New Mexico College of Pharmacy  
Percent effort: 10%  
Project period: 1/1/17 through 6/30/17

5. *Relationship of HbA1c and platelet aggregation response to aspirin in patients with type 2 DM*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Snowden SS, Anderson JR, Ahmed BA, Bouchonville MF, Ray GR  
Amount funded: \$14,873 + \$7,676  
Funding sources: University of New Mexico Clinical & Translational Science Center + University of New Mexico School of Medicine  
Percent effort: 5%  
Project period: 12/1/12 through 6/30/14



6. *Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS)*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigators: Ahmed B, **Nawarskas JJ**  
Co-Investigators: Snowden SS, Anderson JR  
Amount funded: \$41,940  
Funding sources: Lilly USA, LLC  
Percent effort: 2.5%  
Project period: 1/23/12 through 1/22/17

7. *Sex-Specific Differences In The Protective Effect Of Statins On Skeletal Fractures*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Bakhireva LN  
Co-Investigators: **Nawarskas JJ**, Shainline, MR, Robinson, SB, Gunter MJ, Carter S, Beaton SJ  
Amount funded: \$25,000  
Funding sources: American College of Clinical Pharmacy Research Institute (\$15,000)  
UNM HSC Research Allocation Committee (\$10,000)  
Percent effort: 2%  
Project period: 2/1/08 through 1/31/09

8. *Cardiovascular Risk Reduction Clinic Outcomes Assessment*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Anderson JR  
Co-Investigators: **Nawarskas JJ**, Juttila C, Collieran KM, Borrego ME  
Amount funded: \$99,891 extramurally + GCRC support  
Funding sources: Pfizer Pharmaceuticals (\$99,891)  
University of New Mexico General Clinical Research Center (GCRC)  
(M01 RR00997; NCRR-GCRC)  
Percent effort: 7%  
Project period: 7/1/02 through 6/30/09

9. *Comparison of Hydrochlorothiazide and Metolazone in Combination with Furosemide in Congestive Heart Failure Patients*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Anderson JR  
Co-Investigators: **Nawarskas JJ**, Taylor RA  
Amount funded: \$7,150 + GCRC support  
Funding sources: University of New Mexico Research Allocation Committee (\$7,150)  
University of New Mexico General Clinical Research Center (GCRC)  
(M01 RR00997; NCRR-GCRC)  
Percent effort: 2%  
Project period: 7/1/02 through 6/30/09

10. *Characterization of an Aspirin-Ibuprofen Interaction*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Anderson JR, Hrebickova L, Timm TC  
Amount funded: \$20,000  
Funding sources: American College of Clinical Pharmacy Research Institute (\$10,000)  
 American Association of Colleges of Pharmacy (\$10,000)  
 University of New Mexico General Clinical Research Center (GCRC)  
 (M01 RR00997; NCRR-GCRC)  
Percent effort: 20%  
Project period: 7/1/02 through 6/30/08

11. *A Comparison of the Antiplatelet Effects of 81 and 325 mg of Aspirin Administered Once Daily*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigator: Timm TC  
Amount funded: \$2,900  
Funding source: University of New Mexico General Clinical Research Center  
 (M01 RR00997; NCRR-GCRC)  
Percent effort: 5%  
Project period: 7/1/02 though 6/30/08

12. *Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM)*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Taylor RA  
Co-Investigators: **Nawarskas JJ**, Anderson JR, O'Connell AM, Crawford MH, Kelly FM  
Amount funded: \$58,000  
Funding sources: AstraZeneca, LP  
Percent effort: 2%  
Project period: 7/1/99 through 6/30/03

13. *A Multicenter, Randomized, Double-Blind, Placebo-Controlled "Factorial" Design study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients with Primary Hypercholesterolemia*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Colleran KM  
Co-Investigators: **Nawarskas JJ**, Anderson JR, Kelly FM  
Amount funded: To be determined  
Funding source: Merck & Co., Inc.  
Percent effort: 2%  
Project period: 8/1/02 through 7/31/03

14. *A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/day and Fenofibrate 160 mg/day Compared to Simvastatin 20 mg/day Alone for 12 weeks of Treatment in Patients with Combined Hyperlipidemia - Simvastatin and Fenofibrate Efficacy Trial (SAFARI)*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Colleran KM  
Co-Investigators: **Nawarskas JJ**, Anderson JR, Kelly FM  
Amount funded: To be determined  
Funding source: Merck & Co., Inc.  
Percent effort: 2%  
Project period: 7/1/02 through 6/30/03

15. *Comparative Antiplatelet Effects of Aspirin and Purple Grape Juice in Healthy Volunteers*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Anderson JR, Krein J, Raizada V  
Amount funded: \$16,505  
Funding sources: University of New Mexico General Clinical Research Center (\$11,505) (M01 RR00997; NCRR-GCRC)  
 University of New Mexico Research Allocation Committee (\$5000)  
Percent effort: 20%  
Project period: 7/1/00 though 6/30/02

16. *Cardiovascular Risk Reduction Clinic Equipment Request*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: **Nawarskas JJ**  
Co-Investigators: Anderson JR, Colleran KM, Taylor RA, Borrego ME  
Amount funded: \$26,850  
Funding source: University of New Mexico Health Sciences Center  
Percent effort: Not applicable  
Project period: Not applicable; one-time funding request

17. *Clinical Pharmacy Demonstration Project*

Research Affiliation: Health Centers of Northern New Mexico and University of New Mexico Health Sciences Center  
Principal Investigator: Gupchup GV  
Co-Investigators: **Nawarskas JJ**, Anderson JR, Colleran KM  
Amount funded: \$70,177  
Funding sources: DHHS/PHS/HRSA/OPA  
Percent effort: 5%  
Project period: 7/1/01 though 6/30/02

18. *Randomized Etanercept North American Strategy to Study Antagonism of Cytokines (RENAISSANCE)*

Research Affiliation: University of New Mexico Health Sciences Center  
Principal Investigator: Abrams J  
Co-Investigators: Nawarskas JJ, Anderson JR, O'Connell AM, Kelly FM  
Amount funded: \$77,553  
Funding sources: Immunex Pharmaceuticals  
Percent effort: 2%  
Project period: 7/1/99 through 6/30/01

19. *The Influence of Aspirin on the Hypotensive Efficacies of Enalapril and Losartan*

Research Affiliation: Philadelphia College of Pharmacy and Science and University of Pennsylvania.  
Principal Investigator: Nawarskas JJ  
Co-Investigators: Spinler SA, Townsend RR, Cirigliano MD  
Amount funded: Undetermined amount; research supported by General Clinical Research Center at the Hospital of the University of Pennsylvania  
Funding sources: General Clinical Research Center at the Hospital of the University of Pennsylvania (NIH grant #M01-RR00040-96)  
Percent effort: 20%  
Project period: 1/1/96 through 9/30/97

20. *Antiplatelet Effect of Rectal Versus Oral Aspirin in Healthy, Middle-Aged Volunteers*

Research Affiliation: Philadelphia College of Pharmacy and Science and University of Pennsylvania.  
Principal Investigator: Spinler SA  
Co-Investigators: Nawarskas JJ, Cheng JWM, FitzGerald GA, Catella-Lawson F  
Amount funded: \$15,000 + GCRC support  
Funding sources: United States Pharmacopeia (\$15,000)  
 General Clinical Research Center at the Hospital of the University of Pennsylvania (NIH grant #M01-RR00040-96)  
Percent effort: 10%  
Project period: 5/1/96 through 6/30/97

21. *Predictive Performance of Eleven Methods for Estimating Creatinine Clearance in Patients with Stable Renal Function: Effects of Renal Insufficiency, Obesity, Age, Low Serum Albumin, and Low Serum Creatinine. Subgroup Analysis of the Iohexol Cooperative Study*

Research Affiliation: Philadelphia College of Pharmacy and Science  
Principal Investigator: Spinler SA  
Co-Investigators: Nawarskas JJ, Charland SC, Connors J, Boyce E, Goldfarb S  
Amount funded: Undetermined amount; partially funded by Sanofi-Winthrop Pharmaceuticals  
Funding source: Sanofi-Winthrop Pharmaceuticals  
Percent effort: 5%  
Project period: 10/1/95 through 8/31/97

22. *Infectious Complications of AICD Implantations at The University of Pennsylvania Medical Center: A Retrospective Case Review*

Research Affiliation: Philadelphia College of Pharmacy and Science and University of Pennsylvania  
Principal Investigator: Spinler SA  
Co-Investigators: Nawarskas JJ, Foote EF, Sabapathi D, Connors JE, Marchlinski FE  
Amount funded: Undetermined amount; partially funded by Upjohn Pharmaceuticals  
Funding source: Upjohn Pharmaceuticals  
Percent effort: 5%  
Project period: 10/1/95 through 8/31/97

23. *Organization to Assess Strategies for Ischemic Syndromes (OASIS) Acute Ischemic Syndromes Registry*

Research Affiliation: Philadelphia College of Pharmacy and Science, University of Pennsylvania, and Philadelphia Veterans Administration Medical Center  
Principal Investigator: Spinler SA  
Co-Investigators: Nawarskas JJ, Cheng JWM, Kolansky DM, Laskey WK  
Amount funded: \$3000  
Funding source: Canadian Cardiovascular Collaboration  
Percent effort: 5%  
Project period: 10/1/95 through 6/30/97

24. *The Effects of Gender on Adrenergic Receptor Responsiveness*

Research Affiliation: State University of New York at Buffalo and Millard Fillmore Hospital  
Principal Investigator: Luzier AB  
Co-Investigators: Nawarskas JJ, Anonuevo J, Wilson MF, Kazierad DJ  
Amount funded: Unfunded  
Funding source: Unfunded  
Percent effort: 5%  
Project period: 7/1/94 through 8/31/95

**PUBLICATIONS:**

**Publications in Peer-reviewed Journals:**

1. Schluez LA, Ramos-Otero GP, Nawarskas JJ. Chloroquine or hydroxychloroquine for management of coronavirus disease 2019: friend or foe? *Cardiol Rev* 2020;28:266-271.
2. Shyh GI, Nawarskas JJ, Cheng-Lai A. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with coronavirus disease 2019: friend or foe? *Cardiol Rev* 2020;28:213-216.
3. Nawarskas JJ, Shephard EA. Tafamidis: a novel treatment for transthyretin amyloid cardiomyopathy. *Cardiol Rev* 2020;28:156-160.

4. **Nawarskas JJ**, Shephard EA. Nitrosamine impurities in angiotensin receptor blockers. *Cardiol Rev* 2020;28:262-265.
5. Felton LA, Lauber DA, Koury J, **Nawarskas JJ**. An explanation for the effect of different storage conditions on sublingual nitroglycerin tablet stability. *Am J Cardiol* 2019;124:990-991.
6. Sible AM, **Nawarskas JJ**. Andexanet alfa for reversing factor Xa inhibition. *Cardiol Rev* 2019;27:108-111.
7. **Nawarskas JJ**, Koury J, Lauber DA, Felton LA. Open-label study of the stability of sublingual nitroglycerin tablets in simulated real-life conditions. *Am J Cardiol*. 2018;122:2151-2156.
8. Henrie AM, Sather MR, Bakhireva LN, **Nawarskas JJ**, Boardman KD, Huang GD. Impact of Department of Veterans Affairs Cooperative Studies Program clinical trials on practice guidelines for high blood pressure management. *Contemp Clin Trials Commun* 2018;13:100313.
9. Lewis-Gonzalez JM, **Nawarskas JJ**. Are shorter durations of dual antiplatelet therapy acceptable following percutaneous coronary intervention? *Cardiol Rev* 2018;26:213-217.
10. Hamidovic A, Candelaria L, Rodriguez I, Yamada M, **Nawarskas J**, Burge MR. Learning and memory performance following acute intranasal insulin administration in abstinent smokers. *Hum Psychopharmacol* 2018;33:e2649.
11. **Nawarskas JJ**, Montoya TN. Switching from ticagrelor or prasugrel to clopidogrel. *Cardiol Rev* 2018;26:107-111.
12. **Nawarskas JJ**, Cheng-Lai A, Frishman WH. Celiprolol: a unique selective adrenoceptor modulator. *Cardiol Rev* 2017;25:247-253.
13. Sible AM, **Nawarskas JJ**. Cangrelor: A new route for P2Y<sub>12</sub> inhibition. *Cardiol Rev* 2017;25:133-139.
14. Bowman BN, **Nawarskas JJ**, Anderson JR. Treating diuretic resistance: and overview. *Cardiol Rev* 2016;24:256-60.
15. Sible AM, **Nawarskas JJ**, Anderson JR. PCSK9 inhibitors: an innovative approach to treating hyperlipidemia. *Cardiol Rev* 2016;24:141-52.
16. Marshik PL, Kharat AA, Jakeman B, Borrego ME, Dodd MA, Bachyrycz A, Anderson JR, Bond R, Deming P, Mercier RC, **Nawarskas JJ**, Ray G, Salazar K. Complementary and alternative medicine and therapy use in a diverse New Mexican population. *J Altern Complement Med* 2016;22:45-51.
17. Sible AM, **Nawarskas JJ**, Alajajian D, Anderson JR. Sacubitril/valsartan: A novel cardiovascular combination agent. *Cardiol Rev* 2016;24:41-7.
18. **Nawarskas JJ**, Newsome C, Anderson JR, Ahmed B. P2Y<sub>12</sub> inhibitors for acute coronary syndromes: current perspectives. *Res Rep Clin Cardiol* 2015;6:123-43.
19. Henrie AM, **Nawarskas JJ**, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. *Core Evid* 2015;10:99-109.

20. Cung H, Aragon MJ, Zychowski K, Anderson JR, **Nawarskas J**, Roldan C, Sood A, Qualls C, Campen MJ. Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients. *J Transl Med* 2015;13:99.
21. **Nawarskas JJ**, Bowman BN, Anderson JR. Ivabradine: A unique and intriguing medication for treating cardiovascular disease. *Cardiol Rev* 2015;23:201-11.
22. Roberts DI, **Nawarskas JJ**. Treatment options for patients with poor clopidogrel response. *Cardiol Rev* 2013;21:309-17.
23. Garg V, Shen X, Cheng Y, **Nawarskas JJ**, Raisch DW. Use of number needed to treat in cost-effectiveness analyses. *Ann Pharmacother* 2013;47:380-7.
24. Ray GM, **Nawarskas JJ**, Anderson JR. Blood pressure monitoring technique impacts hypertension treatment. *J Gen Intern Med* 2012;27:623-9.
25. Goswami S, Cheng-Lai A, **Nawarskas J**. Clopidogrel and genetic testing: is it necessary for everyone? *Cardiol Rev* 2012;20:96-100.
26. **Nawarskas JJ**, Snowden SS. Critical appraisal of ticagrelor in the management of acute coronary syndrome. *Ther Clin Risk Manag* 2011;7:473-88.
27. **Nawarskas JJ**, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. *Cardiol Rev* 2011;19:95-100.
28. Bakhireva LN, Shainline MR, Carter S, Robinson S, Beaton SJ, **Nawarskas JJ**, Gunter MJ. Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. *Pharmacotherapy* 2010;30:879-87.
29. Anderson JR, **Nawarskas JJ**. Pharmacotherapeutic management of pulmonary arterial hypertension. *Cardiol Rev* 2010;18:148-62.
30. Neff KM, **Nawarskas JJ**. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. *Cardiol Rev* 2010;18:51-6.
31. Raisch DW, **Nawarskas JJ**. Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm values. *Expert Rev Pharmacoecon Outcomes Res* 2009;9:99-102.
32. Koo MH, **Nawarskas JJ**, Frishman WH. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. *Cardiol Rev* 2008;16:314-8.
33. Boyd A, **Nawarskas J**. Metformin use in decompensated heart failure. *Cardiol Rev* 2008;16:269-72.
34. Ray GM, **Nawarskas JJ**, Frishman WH. The paclitaxel-eluting stent in percutaneous coronary intervention. Part II: Comparison to the sirolimus-eluting stent, economics, and unanswered questions. *Cardiol Rev* 2006;14:143-50.
35. Nguyen T, Frishman WH, **Nawarskas J**, Lemer RG. Variability of response to clopidogrel: possible mechanisms and clinical implications. *Cardiol Rev* 2006;14:88-98.

36. Gruchalla KJA, **Nawarskas JJ**. The paclitaxel-eluting stent in percutaneous coronary intervention. Part I: Background and clinical comparison to bare-metal stents. *Cardiol Rev* 2006;14:88-98.
37. **Nawarskas JJ**, Osborn LA. Paclitaxel-eluting stents in coronary artery disease. *Am J Health-Syst Pharm* 2005;62:2241-51.
38. Anderson JR, **Nawarskas JJ**. Ranolazine: a metabolic modulator for the treatment of chronic stable angina. *Cardiol Rev* 2005;13:202-210.
39. **Nawarskas JJ**. HMG-CoA reductase inhibitors and coenzyme Q10. *Cardiol Rev* 2005;13:76-9.
40. **Nawarskas JJ**. Clopidogrel-statin interaction. *Cardiol Rev* 2004;12:236-9.
41. Hrebickova L, **Nawarskas JJ**, Anderson JR. Ximelagatran: A new oral anticoagulant. *Heart Disease* 2003;5:397-408.
42. Moore TD, **Nawarskas JJ**, Anderson JR. Eplerenone: A selective aldosterone receptor antagonist for hypertension and heart failure. *Heart Disease* 2003;5:354-63.
43. **Nawarskas JJ**, Anderson JR. Levosimendan: A unique approach to the treatment of heart failure. *Heart Disease* 2002;4:265-71.
44. **Nawarskas J**, Rajan V, Frishman WH. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. *Heart Disease* 2001;3:378-85.
45. Anderson JR, Khou S, **Nawarskas JJ**. Ranolazine: A potential new treatment for chronic stable angina. *Heart Disease* 2001;3:263-9.
46. **Nawarskas JJ**, Anderson JR. Bivalirudin: A new approach to anticoagulation. *Heart Disease* 2001;3:131-7.
47. **Nawarskas JJ**, Anderson JR. Omapatrilat: A unique new agent for the treatment of cardiovascular disease. *Heart Dis* 2000;2:266-74.
48. Daniel TA, **Nawarskas JJ**. Vitamin C in the prevention of nitrate tolerance. *Ann Pharmacother* 2000;34:1193-7.
49. **Nawarskas JJ**, Spinler SA. Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors. *Pharmacotherapy* 2000;20:698-710.
50. **Nawarskas JJ**, Townsend RR, Cirigliano MD, Spinler SA. The effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. *Am J Hypertens* 1999;12:784-9.
51. **Nawarskas JJ**. Acadesine. A unique cardioprotective agent for myocardial ischemia. *Heart Disease* 1999;1:255-60.
52. Spinler SA, **Nawarskas JJ**, Boyce EG, Connors JE, Charland SL, Goldfarb S. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. *Ann Pharmacother* 1998;32:1275-83.



53. Luzier AB, **Nawarskas JJ**, Añonuevo J, Wilson MF, Kazierad DJ. The effects of gender on adrenergic receptor responsiveness. *J Clin Pharmacol* 1998;38:618-24
54. **Nawarskas JJ**, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? *Pharmacotherapy* 1998; 18:1041-52.
55. Spinler SA, **Nawarskas JJ**, Foote EF, Sabapathi D, Connors JE, Marchlinski FE. Clinical presentation and analysis of risk factors for infectious complications of implantable cardioverter-defibrillator implantations at a University Medical Center. *Clin Infect Dis* 1998;26:1111-6.
56. Spinler SA, **Nawarskas JJ**. Low-molecular-weight heparins for acute coronary syndromes. *Ann Pharmacother* 1998;32:103-10.
57. **Nawarskas JJ**, McCarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. *Ann Pharmacother* 1997;31:864-6.
58. Mauro LS, **Nawarskas JJ**, Mauro VF. Misadventures with activated charcoal and recommendations for safe use. *Ann Pharmacother* 1994;28:915-24.

#### **Invited Publications:**

1. **Nawarskas JJ**. Book review: Pharmacotherapy: A Pathophysiologic Approach, 8<sup>th</sup> ed. *Ann Pharmacother* 2011;11:Epub.
2. **Nawarskas JJ**, Cheng-Lai A. Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. *Sociedad Iberoamericana de Información Científica*.
3. **Nawarskas J**. Does aspirin interfere with ACE inhibitors in CVD treatment? *Today in Cardiology* 2002;5:18.
4. Anderson JR, **Nawarskas JJ**. Cardiovascular drug-drug interactions. *Cardiology Clinics* 2001;19:215-34.

#### **Books:**

Cheng-Lai A, **Nawarskas JJ**, Frishman WH. Handbook of Hypertension Management. Baltimore, Lippincott Williams & Wilkins, 2007.

#### **Book Chapters:**

1. **Nawarskas JJ**. Hypertensive Crisis. In: Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook. A Patient-Focused Approach, 11<sup>th</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 11<sup>th</sup> ed., New York, McGraw-Hill Education, 2020.

2. **Nawarskas JJ.** Hypertensive Crisis. In: Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook. A Patient-Focused Approach, 10<sup>th</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 10<sup>th</sup> ed., New York, McGraw-Hill, 2017.
3. **Nawarskas JJ.** Hypertensive Crisis. In: Schwinghammer TL, Koehler JM, eds. Pharmacotherapy Casebook. A Patient-Focused Approach, 9<sup>th</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 9<sup>th</sup> ed., New York, McGraw-Hill, 2014.
4. **Nawarskas JJ.** Hypertensive Crisis. In: Schwinghammer TL, Koehler JM, eds. Pharmacotherapy Casebook. A Patient-Focused Approach, 8<sup>th</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 8<sup>th</sup> ed., New York, McGraw-Hill, 2011.
5. **Nawarskas JJ, Ricciardi MJ.** Drug-Eluting Stents. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3<sup>rd</sup> ed. Minneapolis, Cardiotext Publishing, 2011.
6. Cheng-Lai A, **Nawarskas JJ**, Frishman WH. Cardiovascular Drug-Drug Interactions. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3<sup>rd</sup> ed. Minneapolis, Cardiotext Publishing, 2011.
7. Frishman WH, **Nawarskas JJ**, Anderson JR. Ranolazine: A Piperazine Derivative. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3<sup>rd</sup> ed. Minneapolis, Cardiotext Publishing, 2011.
8. Lam S, **Nawarskas J**, Cheng-Lai A. Hematology and Immunology. In: Hutchison LC, Sleeper RB, eds. Fundamentals of Geriatric Pharmacotherapy: An Evidence-Based Approach. Bethesda, American Society of Health-System Pharmacists, 2010.
9. **Nawarskas JJ.** Antihypertensive drugs. In: Smith K, Riche DM, Henyan N, eds. Handbook of Clinical Drug Data, 11<sup>th</sup> ed. New York, McGraw-Hill, 2010.
10. **Nawarskas JJ.** Hypertensive urgency. In: Schwinghammer TL, Koehler J, eds. Pharmacotherapy Casebook. A Patient-Focused Approach, 5<sup>th</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 5<sup>th</sup> ed., Stamford, Appleton & Lange, 2008.
11. **Nawarskas JJ.** Hypertensive urgency. In: Schwinghammer TL, ed. Pharmacotherapy Casebook. A Patient-Focused Approach, 4<sup>th</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 4<sup>th</sup> ed., Stamford, Appleton & Lange, 2005.
12. Frishman WH, **Nawarskas J**, Rajan V, Sica DA. Vasopeptidase inhibitors, neutral endopeptidase inhibitors and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. In Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2<sup>nd</sup> ed. New York, McGraw Hill, 2003 (in press).
13. **Nawarskas J.** Pharmacologic Management of Chronic Stable Angina. In: Cheng JWM, ed. Quick Reference to Cardiovascular Pharmacotherapy, 1<sup>st</sup> ed. Boca Raton, CRC Press, 2002.
14. **Nawarskas J.** Pharmacologic Management of Acute Coronary Syndromes. In: Cheng JWM, ed. Quick Reference to Cardiovascular Pharmacotherapy, 1<sup>st</sup> ed. Boca Raton, CRC Press, 2002.
15. **Nawarskas J.** Pharmacologic Management of Thromboembolic Diseases. In: Cheng JWM, ed.

Quick Reference to Cardiovascular Pharmacotherapy, 1<sup>st</sup> ed. Boca Raton, CRC Press, 2002.

16. **Nawarskas JJ.** Antihypertensive drugs. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data, 10<sup>th</sup> ed. New York, McGraw-Hill, 2002.
17. **Nawarskas JJ.** Hypertensive urgency. In: Schwinghammer TL, ed. Pharmacotherapy Casebook. A Patient-Focused Approach, 3<sup>rd</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 3<sup>rd</sup> ed., Stamford, Appleton & Lange, 2002.
18. **Nawarskas JJ.** Lipid-lowering drugs. In: Frishman WH, Cheng-Lai A, Chen J, eds. Current Cardiovascular Drugs, 3<sup>rd</sup> ed. Philadelphia, Current Science Inc., 2000.
19. **Nawarskas JJ.** Hypertensive urgency. In: Schwinghammer TL, ed. Pharmacotherapy Casebook. A Patient-Focused Approach, 2<sup>nd</sup> ed., and Instructor's Guide to Accompany Pharmacotherapy Casebook. A Patient-Focused Approach, 2<sup>nd</sup> ed., Stamford, Appleton & Lange, 2000.
20. **Nawarskas JJ.** Ticlopidine and clopidogrel. In: Crawford MH, ed. Cardiology Clinics: Annual of Drug Therapy, 3<sup>rd</sup> ed. Philadelphia, W.B. Saunders Company, 1999.
21. **Nawarskas JJ.** Antihypertensive drugs. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data, 9<sup>th</sup> ed. Stamford, Appleton & Lange, 1999.
22. **Nawarskas JJ, Crawford MH.** Recent developments in the treatment of hypertensive crises. In: Crawford MH, ed. Cardiology Clinics: Annual of Drug Therapy, 2<sup>nd</sup> ed. Philadelphia, W.B. Saunders Company, 1998.

#### Letters:

1. **Nawarskas JJ, Spinler SA.** Additional anticoagulant strategies for the management of heparin-induced thrombocytopenia (letter). *Am J Health-Syst Pharm* 1996;53:945.
2. Spinler SA, **Nawarskas JJ.** Are the drug names "Coumadin" and "warfarin" interchangeable? (letter). *J Am Coll Cardiol* 1996;27:1552-3.

#### Abstracts:

1. Cung H, Anderson J, **Nawarskas J**, Campen M. Circulating inflammatory potential measured by an endothelial biosensor assay in coronary artery disease patients [abstract 20478]. *Circulation* 2014;130:A20478.
2. Robles L Bakhireva L, **Nawarskas J.** Predictors of receiving and adhering to hypertension therapeutic and lifestyle modification management [abstract PCV113]. *Value Health* 2012;A133-A134. "Green Ribbon" poster finalist.
3. Marshik PM, Ray GM, **Nawarskas JJ**, et al. Attitudes, experience and use regarding complementary and alternative medicines and therapies (CAMT) in people living in New Mexico [abstract 175]. *J Am Pharm Assoc* 2012;52:246.
4. Anderson JR, Gupchup GV, Martinez C, Colson LC, **Nawarskas JJ.** Clinical impact of the addition of a pharmacist clinician to the management of patients enrolled in a diabetes disease state

management program [abstract 024]. *J Am Pharm Assoc* 2005.

5. **Nawarskas JJ**, Hrebickova L, Anderson JR, Timm TC. Aventis Cardiovascular Investigator Development Research Award: Characterization of an aspirin-ibuprofen interaction [abstract 438]. *Pharmacotherapy* 2004;24:1481-2.
6. **Nawarskas JJ**, Anderson JR, Raizada V. Whole blood aggregometry as a potential method of detecting aspirin resistance [abstract 1009-119]. *J Am Coll Cardiol* 2003;41(suppl A):226A.
7. Gupchup GV, Anderson JR, **Nawarskas J**, Vigil C, Colleran K. Clinical pharmacy demonstration project at Health Centers of Northern New Mexico. *International Pharmaceutical Abstracts, ASHP Midyear Clinical Meeting*, 2002;37 (Dec), pCPDP-15.
8. **Nawarskas JJ**, Anderson JR, Kriehn J, Raizada V. Purple grape juice inferior to aspirin as antiplatelet agent [abstract 40]. *Pharmacotherapy* 2002;22:1331.
9. Dodd MA, **Nawarskas JJ**, Anderson JR, Crawford MH. Underutilization of  $\beta$ -blockers and ACE inhibitors in a Medicaid CHF population [abstract 320]. *J Cardiac Failure* 2001;7:87.
10. **Nawarskas JJ**, Townsend RR, Cirigliano MD, Spinler SA. Lack of interaction between aspirin and either enalapril or losartan in hypertensive patients [abstract 25]. *Pharmacotherapy* 1998;18:1142.
11. **Nawarskas JJ**, Charland SL, Boyce EG, Connors JE, Goldfarb S, Spinler SA, for the Iohexol Cooperative Study. Predictive performance of eleven methods for calculating creatinine clearance in cardiac patients with stable renal function: effect of low serum creatinine [abstract 50]. *Pharmacotherapy* 1997;17:190.
12. Spinler SA, **Nawarskas JJ**, Boyce EG, Connors JE, Charland SL, Goldfarb S, for the Iohexol Cooperative Study. Predictive performance of eleven methods for calculating creatinine clearance in cardiac patients with stable renal function: effect of renal insufficiency [abstract 51]. *Pharmacotherapy* 1997;17:190-1.
13. Spinler SA, **Nawarskas JJ**, Connors JE, Boyce EG, Charland SL, Goldfarb S, for the Iohexol Cooperative Study. Predictive performance of eleven methods for calculating creatinine clearance in cardiac patients with stable renal function: effect of obesity [abstract 52]. *Pharmacotherapy* 1997;17:191.
14. **Nawarskas JJ**, Boyce EG, Connors JE, Charland SL, Goldfarb S, Spinler SA, for the Iohexol Cooperative Study. Predictive performance of eleven methods for calculating creatinine clearance in cardiac patients with stable renal function: effect of age [abstract 53]. *Pharmacotherapy* 1997;17:191.
15. **Nawarskas JJ**, Luzier AB, Anonuevo J, Wilson MF, Kazierad DJ. Gender effects on adrenergic receptor sensitivity [abstract PIII-12]. *Clin Pharmacol Ther* 1996;59:191.

## PRESENTATIONS:

### Invited Presentations:

1. *“Standardized Patient Assessment of Communications in Pharmacy and Medical Students”*  
American Association of Colleges of Pharmacy Annual Meeting, Chicago, IL  
July 15, 2019
2. *“Prevention of Cardiovascular Disease in the Patient with Diabetes”*  
New Mexico Diabetes Advisory Council; Albuquerque, NM  
December 7, 2018
3. *“Focused Update: The 2017 ACC/AHA Hypertension Guidelines”*  
UNM College of Pharmacy Preceptor Development Series; Albuquerque, NM  
March 20, 2018
4. *“Antiplatelet Drugs”*  
Cardiology TeleECHO (Extension for Community Healthcare Outcomes); Albuquerque, NM  
October 16, 2017
5. *“Antiplatelet Drugs”*  
Cardiology TeleECHO (Extension for Community Healthcare Outcomes); Albuquerque, NM  
January 30, 2017
6. *“Blood Pressure Measurement & Monitoring in Contemporary Practice”*  
New Mexico Pharmacists Association 87<sup>th</sup> Annual Convention; Albuquerque, NM  
June 25, 2016
7. *“Hypertension Treatment: Current Guidelines and Future Directions”*  
New Mexico Pharmacists Association 2016 Mid-Winter Meeting; Albuquerque, NM  
January 24, 2016
8. *“Applying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patient, Parts I and II”*  
New Mexico Society of Health-Systems Pharmacists 2014 Balloon Fiesta Symposium;  
Albuquerque, NM  
October 5, 2014
9. *“New Oral Antiplatelet Agents for Coronary Artery Disease”*  
New Mexico Pharmacists Association 83<sup>rd</sup> Annual Convention, Albuquerque, NM  
June 24, 2012
10. *“2009 Update in Antiplatelet Therapy”*  
Preceptorships in the Management of Anticoagulation Therapy and Clinical Thrombosis,  
Albuquerque, NM  
November 6, 2009
11. *“2008 Update in Antiplatelet Therapy”*  
Anticoagulation: Advanced Preceptorship in the Management of Anticoagulation Therapy and  
Clinical Thrombosis, Albuquerque, NM  
November 7, 2008

12. *"Cardiovascular Risk Reduction in Patients with Diabetes"*  
Zia Association of Diabetes Educators Fall 2008 Conference, Albuquerque, NM  
September 27, 2008
13. *"2007 Antiplatelet Therapy Update"*  
Anticoagulation: Advanced Preceptorship in the Management of Anticoagulation Therapy and  
Clinical Thrombosis, Albuquerque, NM  
November 2, 2007
14. *"Antiplatelet Therapy in the Anticoagulation Clinic"*  
Anticoagulation: Advanced Preceptorship in the Management of Anticoagulation Therapy and  
Clinical Thrombosis, Albuquerque, NM  
November 2006
15. *"Treating Ischemic Heart Disease in 2005: Update and Controversies"*  
New Mexico Society of Health-Systems Pharmacists (NMSHP) Balloon Fiesta Meeting,  
Albuquerque, NM; October, 2005
16. *"Emerging Concepts in Dyslipidemia Management"*  
New Mexico Academy of Physician Assistants Fall Primary Care Update, Albuquerque, NM;  
September, 2004.
17. *"Emerging Concepts in Dyslipidemia Management"*  
NMSHP Dinner Meeting, Albuquerque, NM; June 30, 2004.
18. *"Emerging Concepts in Dyslipidemia Management"*  
El Paso Society of Health-Systems Pharmacists, El Paso, TX; March, 2004.
19. *"After a Heart Attack: Drugs to Use, Drugs to Avoid, and Everything In -Between"*  
NMSHP Spring Meeting, Santa Fe, NM; March 22, 2003.
20. *"Cardiovascular Risk Reduction: Opportunities for Community Pharmacists"*  
New Mexico Pharmaceutical Association Winter Meeting, Albuquerque, NM; January 19, 2003.
21. *"Update of Drug Therapy for Chronic Heart Failure"*  
New Mexico Society of Health-Systems Pharmacists 14<sup>th</sup> Annual Meeting & Balloon Fiesta  
Symposium, Albuquerque, NM; October 8, 2002.
22. *"Outpatient Drug Management of Ischemic Heart Disease"*  
New Mexico Academy of Physician Assistants Fall Primary Care Update, Albuquerque, NM;  
September 29, 2002.
23. *"Promoting the Prevention of Cardiovascular Disease"*  
New Mexico Pharmaceutical Association 72<sup>nd</sup> Annual Convention, Albuquerque, NM; June 24,  
2001.
24. *"The ABC's of Post-MI Treatment"*  
New Mexico Society of Health-Systems Pharmacists Dinner Meeting, Albuquerque, NM;  
January 30, 2001.
25. *"Does Aspirin Interfere with the Therapeutic Efficacy of ACE Inhibitors in Hypertension or  
Congestive Heart Failure?"*

1999 New Mexico Society of Health-Systems Pharmacists Balloon Fiesta Meeting, Albuquerque, NM; October 8, 1999.

26. *“Ticlopidine and Clopidogrel: Clinical Pearls”*  
New Mexico Pharmaceutical Association 70<sup>th</sup> Annual Convention, Albuquerque, NM; June 27, 1999.
27. *“Recent Advances in the Pharmacologic Treatment of Chronic Congestive Heart Failure”*  
New Mexico Pharmaceutical Association 70<sup>th</sup> Annual Convention, Albuquerque, NM; June 27, 1999.

#### **Research Presentations:**

1. *“Antiplatelet effect and pharmacokinetic comparison of rectal versus oral aspirin in healthy, middle-aged volunteers”*  
1996-1997 United States Pharmacopeia Fellows’ Recognition Event, Bethesda, MD; May 30, 1997.
2. *“Antiplatelet effect and pharmacokinetic comparison of rectal versus oral aspirin in healthy, middle-aged volunteers”*  
Sixteenth Annual Eastern States Residency Conference, Baltimore, MD; May 2, 1997.
3. *“Predictive performance of various methods of estimating creatinine clearance in subgroups of stable patients awaiting coronary angiography”*  
Mid-Atlantic College of Clinical Pharmacy Research Forum, Philadelphia, PA; April 17, 1997.

#### **Poster Presentations:**

1. *“Characterization of an aspirin-ibuprofen interaction”*  
2004 American College of Clinical Pharmacy Annual Meeting, Dallas, TX; October, 2004
2. *“Whole blood aggregometry as a potential method of detecting aspirin resistance”*  
American College of Cardiology 52<sup>nd</sup> Annual Scientific Session, Chicago, IL; March 30, 2003
3. *“Purple grape juice inferior to aspirin as antiplatelet agent”*  
2002 American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM; October 21, 2002.
4. *“Lack of interaction between aspirin and either enalapril or losartan in hypertensive patients”*  
1998 American College of Clinical Pharmacy Annual Meeting, Cincinnati, OH; November 10, 1998.
5. *“Predictive performance of eleven methods for calculating creatinine clearance in cardiac patients with stable renal function: effects of age, renal insufficiency, low serum creatinine, and obesity”*  
1997 American College of Clinical Pharmacy Spring Practice and Research Forum, Panama City Beach, FL; April 8, 1997.
6. *“Gender effects on adrenergic receptor response”*  
American Society for Clinical Pharmacology and Therapeutics 97th Annual Meeting, Orlando, FL; March 22, 1996.

## HONORS & AWARDS:

- 2020: University of New Mexico College of Pharmacy Faculty Appreciation Award ('20 class)
- 2020: University of New Mexico College of Pharmacy Faculty Appreciation Award ('22 class)
- 2019: University of New Mexico College of Pharmacy Faculty Appreciation Award ('21 class)
- 2018: University of New Mexico College of Pharmacy Faculty Appreciation Award ('18 class)
- 2016: University of New Mexico College of Pharmacy Faculty Appreciation Award ('18 class)
- 2015: University of New Mexico College of Pharmacy Teacher of the Year ('15 class)
- 2013: University of New Mexico College of Pharmacy Teacher of the Year ('15 class)
- 2011: University of New Mexico College of Pharmacy Preceptor of the Year ('11 class)
- 2008: University of New Mexico College of Pharmacy Regents Lecturer
- 2007-2008: University of New Mexico College of Pharmacy Teacher of the Year ('10 class)
- 2006-2007: University of New Mexico College of Pharmacy Teacher of the Year ('08 class)
- 2006-2007: University of New Mexico College of Pharmacy Teacher of the Year ('07 class)
- 2004-2005: General Clinical Research Center Glenn T. Peake Clinical Investigator Award
- 2005: University of New Mexico College of Pharmacy Spring Convocation Faculty Speaker
- 2004-2005: University of New Mexico College of Pharmacy Teacher of the Year ('05 class)
- 2003: Marshall, University of New Mexico College of Pharmacy Spring Commencement
- 2002-2003: University of New Mexico College of Pharmacy Teacher of the Year ('03 class)
- 2002: University of New Mexico College of Pharmacy Spring Convocation Faculty Speaker
- 2001: University of New Mexico College of Pharmacy Spring Convocation Faculty Speaker
- 2001: Honorable Mention, AstraZeneca Research Award Advisory Panel for the project entitled: "*Comparative Antiplatelet Effects of Aspirin and Purple Grape Juice in Healthy Volunteers*"
- 2000-2001: University of New Mexico College of Pharmacy Teacher of the Year ('01 class)
- 1999-2000: University of New Mexico College of Pharmacy Teacher of the Year ('00 class)
- 2000: Marshall, University of New Mexico College of Pharmacy Spring Commencement
- 1999: Marshall, University of New Mexico College of Pharmacy Spring Commencement
- 1997: Fellow of the United States Pharmacopeia

## ORGANIZATIONS:

- American Association of College of Pharmacy
- American Society of Health-System Pharmacists
- Rho Chi Pharmacy Honor Society
- Phi Lambda Sigma Pharmacy Leadership Society



## COMMITTEE AND ORGANIZATIONAL WORK:

### National:

#### American Association of Colleges of Pharmacy:

- 2020-present: Distinguished Teaching Scholar Award Panel
- 2016-2019: Delegate

### Regional:

#### New Mexico Society of Health-System Pharmacists:

- 2003-2010: ASHP delegate
- 2005-2007: Chair, Nominations Committee
- 2005-2006: Immediate Past-President
- 2004-2005: President
- 2003-2004: President-elect
- 2002-2003: Alternate ASHP delegate

### Local:

#### University of New Mexico:

- 2019-present: UNM HSC Interprofessional Education Committee
- 2019-present: UNMH/COP Residency Committee (Resident teaching coordinator)
- 2001-present: UNM Hospital Pharmacy & Therapeutics Committee
- 2010-present: Anticoagulation Subcommittee of the Pharmacy & Therapeutics Committee
- 2016-2019: Provost's Committee on Assessment
- 1999-2012: Research Allocation Committee (Nursing/Pharmacy/Allied Health)
- 2011: Clinical Translational Science Center Scholar Search Committee
- 2005-2010: University of New Mexico General Clinical Research Center Advisory Committee
- 2005-2010: Residency Committee
- 2004-2006: Faculty Senator
- 2002-2003: Uncompensated Care Oversight Committee

#### University of New Mexico College of Pharmacy:

- 2020-present: Assessment Committee (Chair)
- 2015-present: Curriculum and Learning Assessment Committee
- 2003-present: Promotion and Tenure Committee (Chair 2014-2020)
- 2014-present: Dean's Advisory Committee for Promotion and Tenure
- 2002-present: Rho Chi Faculty Advisor
- 2015-2019: Assessment Subcommittee of the Curriculum and Learning Assessment Committee (Chair)
- 2014-2015: COP Residency and Fellowship Career Development Committee
- 2012-2015: Admissions Committee
- 2014-2015: Experiential Program Director Search Committee (Chair)
- 2013-2014: Pharmaceutical Care Laboratory Task Force
- 2012-2013: Faculty Development Committee
- 2011-2012: Scholastic Achievement and Progression Committee
- 2011-2012: Curriculum Committee
- 2011-2012: Organization, Planning and Evaluation Committee
- 2011-2012: Search Committee, PEPPOR/Pharmacy Administration Faculty Position

- 2009-2012: Student Honor Council Faculty Advisor
- 2005-2009: Curriculum Committee
- 2003-2007: Scholastic Achievement and Progression Committee
- 2006: Search Committee, Internal Medicine Faculty Position (chair)
- 2001-2004: Search Committee, DeSantis Chair in Pharmacy Administration
- 2004: Search Committee, Pediatric Oncology Faculty Position (chair)
- 2003-2004: Faculty Development Committee (co-chair)
- 2001-2003: Curriculum Committee
- 1998-2001: Pharm.D. Research Committee
- 1998-2000: Faculty Support Committee

#### MISCELLANEOUS SERVICE ACTIVITIES:

- 2005: Local Judge, American Society of Health-System Pharmacists Clinical Skills Competition
- 2001-2003: Coordinator and co-founder, New Mexico Residents' and Fellows' Journal Club
- 2001-2002: Local Judge, American Society of Health-System Pharmacists Clinical Skills Competition
- 2000:
- Graduate Nursing Pharmacology instructor - University of New Mexico College of Nursing
  - Cardiovascular Pharmacology coordinator and instructor - Espanola Partnerships for Training Program in conjunction with the University of New Mexico College of Nursing
  - Cardiovascular Pharmacology instructor - University of New Mexico School of Medicine Physician Assistant Program

#### EDITORIAL APPOINTMENTS:

##### Website Operator:

[www.cardiovascularpharmacotherapeutics.com](http://www.cardiovascularpharmacotherapeutics.com) (went offline in 2015)

##### Textbook Editor:

Frishman WH, Cheng-Lai A, **Nawarskas JJ**, eds. Current Cardiovascular Drugs, 4<sup>th</sup> ed. Philadelphia, Current Medicine LLC, 2005.

##### Section Editor:

2004 - present: *Cardiology in Review*  
2003 - 2004: *Heart Disease*

##### Editorial Board:

2008 - present: *Annals of Pharmacotherapy* (Panel Chair, 2016-present)  
2004 - present: *Cardiology in Review*  
2001 - 2004: *Heart Disease*

*Journal Referee:*

*Annals of Pharmacotherapy*  
*Cardiology in Review*  
*Currents in Pharmacy Teaching and Learning*  
*Current Medical Research & Opinion*  
*Heart Disease* (defunct)  
*Vascular Health and Risk Management*